Idorsia Pharmaceuticals Ltd.

Great valuation partner for biotech companies. I am happy with the performance of your team, good industry knowledge (e.g. development and commercialization of pharma products), good responsiveness and timeline management, flexible attitude, valuation reports and models in line with expectations.

Aprilbio Inc.

I have worked with a different group of people at Venture Valuation to run asset valuation in the last few years. The valuation report was to the point, identifying the area that needs to be improved, and serves as reference during the negotiation process.

Cube Labs SpA

Extraordinary level of technical expertise; excellent reputation and recognition (with reference to their sector) in the European Life Science Market; solid execution and quick delivery

CEO of Biomarker Strategies

Our experience with Venture Valuation was collegial, even during the occasional differences of perspective, which are inevitable. We found the ultimate valuation to be fair and comprehensive.

ZKB Asset Management

Venture Valuation helped us to independently value a large number of companies in a structured and reproducible manner, providing transparency and clear basis for decisions. Great team to work with!

Former CEO of Novartis Venture Fund

We found that the reports were of excellent quality. We can recommend Venture Valuation to all parties that have a need for valuation. We are considering to request further valuations from Venture Valuation.

CEO of APIM Therapeutics AS

Professional service, great interaction with the client, delivery of report according to timelines

CFO of Eutilex Co., Ltd.

Straight forward interaction with the Venture Valuation's team.

CEO of Integra Biosciences

Impressed by fast turn around and delivery in time of a complex content case.

CEO of Legacy Healthcare

In addition to a report which exceeded expectations, the whole process pushed us to review some of the options we initially considered. I strongly recommend the exercise.

Azione Inc.

Venture Valuations delivered a very complex valuation in 2 weeks time. Their team were very accommodating and took the time to dive deep into the explanation of the valuation with a diverse group. The team's genuine interest and enthusiasm in their work shines through with the product they deliver.

CEO of Syngulon

Venture Valuation provides a well-structured, independent opinion on the company's valuation, supported by a detailed report demonstrating their understanding of the company.